Human Tumor Antigens and Cancer Immunotherapy

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Vigneron, Nathalie ^a,b,c  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^b Walloon Excellence in Life Sciences and Biotechnology (WELBIO)   (Belgium)

^c DE DUVE INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; DIFFERENTIATION ANTIGEN; PROTEASOME; TUMOR ANTIGEN; VIRUS ANTIGEN; MONOCLONAL ANTIBODY;

ADOPTIVE TRANSFER; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENDOPLASMIC RETICULUM; ENZYME ACTIVE SITE; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; MASS SPECTROMETRY; MICROSATELLITE INSTABILITY; NONHUMAN; PROMOTER REGION; PROTEIN PROCESSING; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TROPHOBLAST; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES;

EID: 84934344058     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/948501     Document Type: Review

References (190)

1. F. S. Hodi, S. J. O'Day, D. F. McDermott et al., "Improved survival with ipilimumab in patients with metastatic melanoma", The New England Journal of Medicine, vol. 363, no. 8, pp. 711-723, 2010.
2. C. Robert, L. Thomas, I. Bondarenko et al., "Ipilimumab plus dacarbazine for previously untreated metastatic melanoma", The New England Journal of Medicine, vol. 364, no. 26, pp. 2517-2526, 2011.
3. S. L. Topalian, F. S. Hodi, J. R. Brahmer et al., "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer", The New England Journal of Medicine, vol. 366, no. 26, pp. 2443-2454, 2012.
4. S. L. Topalian, C. G. Drake, and D. M. Pardoll, "Targeting the PD-1/B7-H1 (PD-L1) pathway to activate anti-tumor immunity", Current Opinion in Immunology, vol. 24, no. 2, pp. 207-212, 2012.
5. J. R. Brahmer, S. S. Tykodi, L. Q. M. Chow et al., "Safety and activity of anti-PD-L1 antibody in patients with advanced cancer", The New England Journal of Medicine, vol. 366, no. 26, pp. 2455-2465, 2012.
6. S. L. Topalian, M. Sznol, D. F. McDermott et al., "Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab", Journal of Clinical Oncology, vol. 32, no. 10, pp. 1020-1030, 2014.
7. C. Lebbe, J. S. Weber, M. Maio et al., "Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies", Annals of Oncology, vol. 25, no. 11, pp. 2277-2284, 2014.
8. C. Lurquin, A. Van Pel, B. Mariamé et al., "Structure of the gene of tum-transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells", Cell, vol. 58, no. 2, pp. 293-303, 1989.
9. H.-G. Rammensee, K. Falk, and O. Rötzschke, "Peptides naturally presented by MHC class I molecules", Annual Review of Immunology, vol. 11, pp. 213-244, 1993.
10. N. Vigneron and B. J. Van Den Eynde, "Insights into the processing of MHC class I ligands gained from the study of human tumor epitopes", Cellular and Molecular Life Sciences, vol. 68, no. 9, pp. 1503-1520, 2011.
11. Y. Kawakami, P. F. Robbins, X. Wang et al., "Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, - A2, and-A3 alleles", Journal of Immunology, vol. 161, no. 12, pp. 6985-6992, 1998.
12. C. Germeau, W. Ma, F. Schiavetti et al., "High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens", The Journal of Experimental Medicine, vol. 201, no. 2, pp. 241-248, 2005.
13. P. Van Der Bruggen, C. Traversari, P. Chomez et al., "A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma", Science, vol. 254, no. 5038, pp. 1643-1647, 1991.
14. N. Vigneron, W. Ma, A. Michaux, and B. J. Van Den Eynde, "Identifying source proteins formhc class I-presented peptides", Methods in Molecular Biology, vol. 960, pp. 187-207, 2013.
15. V. Brichard, A. Van Pel, T. Wolfel et al., "The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas", The Journal of Experimental Medicine, vol. 178, no. 2, pp. 489-495, 1993.
16. W. Ma, C. Germeau, N. Vigneron et al., "Two new tumor-specific antigenic peptides encoded by gene MAGE-C2 and presented to cytolytic T lymphocytes by HLA-A2", International Journal of Cancer, vol. 109, no. 5, pp. 698-702, 2004.
17. W. Ma, N. Vigneron, J. Chapiro et al., "A MAGE-C2 antigenic peptide processed by the immunoproteasome is recognized by cytolytic T cells isolated from a melanoma patient after successful immunotherapy", International Journal of Cancer, vol. 129, no. 10, pp. 2427-2434, 2011.
18. N. Vigneron, V. Stroobant, B. J. Van Den Eynde, and P. Van Der Bruggen, "Database of T cell-defined human tumor antigens: the 2013 update", Cancer immunity, vol. 13, p. 15, 2013.
19. N. Vigneron, A. Ooms, S. Morel, W. Ma, G. Degiovanni, and B. J. Van Den Eynde, "A peptide derived from melanocytic protein gp100 and presented by HLA-B35 is recognized by autologous cytolytic T lymphocytes on melanoma cells", Tissue Antigens, vol. 65, no. 2, pp. 156-162, 2005.
20. Y. Tomita, K. Imai, S. Senju et al., "A novel tumor-associated antigen, cell division cycle 45-like can induce cytotoxic Tlymphocytes reactive to tumor cells", Cancer Science, vol. 102, no. 4, pp. 697-705, 2011.
21. D. F. Hunt, R. A. Henderson, J. Shabanowitz et al., "characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry", Science, vol. 255, pp. 1261-1263, 1992.
22. R. A. Henderson, H. Michel, K. Sakaguchi et al., "HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation", Science, vol. 255, no. 5049, pp. 1264-1266, 1992.
23. A. L. Cox, J. Skipper, Y. Chen et al., "Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines", Science, vol. 264, no. 5159, pp. 716-719, 1994.
24. M. Schirle, W. Keilholz, B. Weber et al., "Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach", European Journal of Immunology, vol. 30, no. 8, pp. 2216-2225, 2000.
25. A. L. Zarling, J. M. Polefrone, A. M. Evans et al., "Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy", Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 40, pp. 14889-14894, 2006.
26. M. Cobbold, H. De La Peña, A. Norris et al., "MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia", Science Translational Medicine, vol. 5, no. 203, Article ID 203ra125, 2013.
27. J. C. A. Skipper, R. C. Hendrickson, P. H. Gulden et al., "An HLA-A2-restricted tyrosinase antigen on melanoma cells results from post translational modification and suggests a novel pathway for processing of membrane proteins", Journal of Experimental Medicine, vol. 183, no. 2, pp. 527-534, 1996.
28. A. Dalet, P. F. Robbins, V. Stroobant et al., "An antigenic peptide produced by reverse splicing and double asparagine deamidation", Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 29, pp. E323-E331, 2011.
29. T. Boon, P. G. Coulie, B. J. Van Den Eynde, and P. Van Der Bruggen, "Human T cell responses against melanoma", Annual Review of Immunology, vol. 24, pp. 175-208, 2006.
30. P. G. Coulie, B. J. Van Den Eynde, P. Van Der Bruggen, and T. Boon, "Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy", Nature Reviews Cancer, vol. 14, no. 2, pp. 135-146, 2014.
31. D. Iacovides, S. Michael, C. Achilleos, and K. Strati, "Shared mechanisms in stemness and carcinogenesis: lessons from oncogenic viruses", Frontiers in Cellular and Infection Microbiology, vol. 3, article 66, 2013.
32. M. J. P. Welters, G. G. Kenter, S. J. Piersma et al., "Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine", Clinical Cancer Research, vol. 14, no. 1, pp. 178-187, 2008.
33. G. G. Kenter, M. J. P. Welters, A. R. P. M. Valentijn et al., "Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia", The New England Journal of Medicine, vol. 361, no. 19, pp. 1838-1847, 2009.
34. P. G. Coulie, F. Lehmann, B. Lethé et al., "A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma", Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 17, pp. 7976-7980, 1995.
35. Y. Kawakami, X. Wang, T. Shofuda et al., "Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor-infiltrating T lymphocytes", Journal of Immunology, vol. 166, no. 4, pp. 2871-2877, 2001.
36. N. Vigneron, A. Ooms, S. Morel, G. Degiovanni, and B. J. Van Den Eynde, "Identification of a newpeptide recognized by autologous cytolytic T lymphocytes on a humanmelanoma", Cancer Immunity, vol. 2, pp. 9-18, 2002.
37. J. Huang, M. El-Gamil, M. E. Dudley, Y. F. Li, S. A. Rosenberg, and P. F. Robbins, "T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product", Journal of Immunology, vol. 172, no. 10, pp. 6057-6064, 2004.
38. M. Linnebacher, J. Gebert, W. Rudy et al., "Frameshift peptidederived T-cell epitopes: a source of novel tumor-specific antigens", International Journal of Cancer, vol. 93, no. 1, pp. 6-11, 2001.
39. T. Wölfel, M. Hauer, J. Schneider et al., "A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma", Science, vol. 269, no. 5228, pp. 1281-1284, 1995.
40. P. F. Robbins, M. El-Gamil, Y. F. Li et al., "A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes", The Journal of Experimental Medicine, vol. 183, no. 3, pp. 1185-1192, 1996.
41. B. Rubinfeld, P. Robbins, M. El-Gamil, I. Albert, E. Porfiri, and P. Polakis, "Stabilization of β-catenin by genetic defects in melanoma cell lines", Science, vol. 275, no. 5307, pp. 1790-1792, 1997.
42. S. Mandruzzato, F. Brasseur, G. Andry, T. Boon, and P. Van Der Bruggen, "A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma", The Journal of Experimental Medicine, vol. 186, no. 5, pp. 785-793, 1997.
43. V. Lennerz, M. Fatho, C. Gentilini et al., "The response of autologous T cells to a human melanoma is dominated by mutated neoantigens", Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 44, pp. 16013-16018, 2005.
44. M. K. Gjertsen, J. Bjørheim, I. Saeterdal, J. Myklebust, and G. Gaudernack, "Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying thismutation", International Journal of Cancer, vol. 72, no. 5, pp. 784-790, 1997.
45. B. Linard, S. Bézieau, H. Benlalam et al., "A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion", The Journal of Immunology, vol. 168, no. 9, pp. 4802-4808, 2002.
46. ∗0201+ squamous cell carcinomas of the head and neck", International Journal of Cancer, vol. 120, no. 12, pp. 2618-2624, 2007.
47. P. Yotnda, H. Firat, F. Garcia-Pons et al., "Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia", The Journal of Clinical Investigation, vol. 101, no. 10, pp. 2290-2296, 1998.
48. P. Yotnda, F. Garcia, M. Peuchmaur et al., "Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia", Journal of Clinical Investigation, vol. 102, no. 2, pp. 455-462, 1998.
49. C. Lurquin, C. De Smet, F. Brasseur et al., "Two members of the human MAGEB gene family located in Xp21.3 are expressed in tumors of various histological origins", Genomics, vol. 46, no. 3, pp. 397-408, 1997.
50. S. Lucas, C. De Smet, K. C. Arden et al., "Identification of a new MAGE gene with tumor-specific expression by representational difference analysis", Cancer Research, vol. 58, no. 4, pp. 743-752, 1998.
51. P. Chomez, O. De Backer, M. Bertrand, E. De Plaen, T. Boon, and S. Lucas, "An overview of the MAGE gene family with the identification of all human members of the family", Cancer Research, vol. 61, no. 14, pp. 5544-5551, 2001.
52. P. Boel, C. Wildmann, M. L. Sensi et al., "BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes", Immunity, vol. 2, no. 2, pp. 167-175, 1995.
53. B. Van Den Eynde, B. Van Den Eynde, O. Peeters et al., "A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a humanmelanoma", The Journal of Experimental Medicine, vol. 182, no. 3, pp. 689-698, 1995.
54. O. De Backer, K. C. Arden, M. Boretti et al., "Characterization of the GAGE genes that are expressed in various human cancers and in normal testis", Cancer Research, vol. 59, no. 13, pp. 3157-3165, 1999.
55. Y.-T. Chen, M. J. Scanlan, U. Sahin et al., "A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening", Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 5, pp. 1914-1918, 1997.
56. B. Lethé, S. Lucas, L. Michaux et al., "LAGE-1, a new gene with tumor specificity", International Journal of Cancer, vol. 76, no. 6, pp. 903-908, 1998.
57. Ö. Türeci, U. Sahin, I. Schobert et al., "The SSX-2 gene, which is involved in the t (X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40", Cancer Research, vol. 56, no. 20, pp. 4766-4772, 1996.
58. A. O. Gure, Ö. Türeci, U. Sahin et al., "SSX: a multigene family with several members transcribed in normal testis and human cancer", International Journal of Cancer, vol. 72, no. 6, pp. 965-971, 1997.
59. E. De Plaen, K. Arden, C. Traversari et al., "Structure, chromosomal localization, and expression of 12 genes of the MAGE family", Immunogenetics, vol. 40, no. 5, pp. 360-369, 1994.
60. M. A. Gama-Sosa, V. A. Slagel, R. W. Trewyn et al., "The 5-methylcytosine content of DNA from human tumors", Nucleic Acids Research, vol. 11, no. 19, pp. 6883-6894, 1983.
61. M. Ehrlich, M. A. Gama-Sosa, L.-H. Huang et al., "Amount and distribution of 5-methylcytosine in human DNA fromdifferent types of tissues or cells", Nucleic Acids Research, vol. 10, no. 8, pp. 2709-2721, 1982.
62. E. S. Diala, M. S. C. Cheah, D. Rowitch, and R. M. Hoffman, "Extent of DNAmethylation in human tumor cells", Journal of the National Cancer Institute, vol. 71, no. 4, pp. 755-764, 1983.
63. J. Weber, M. Salgaller, D. Samid et al., "Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-Aza-2'-deoxycytidine", Cancer Research, vol. 54, no. 7, pp. 1766-1771, 1994.
64. C. De Smet, C. Lurquin, B. Lethé, V. Martelange, and T. Boon, "DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter", Molecular and Cellular Biology, vol. 19, no. 11, pp. 7327-7335, 1999.
65. L. Sigalotti, E. Fratta, S. Coral et al., "Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-Aza-2'-deoxycytidine", Cancer Research, vol. 64, no. 24, pp. 9167-9171, 2004.
66. G. G. Haas Jr., O. J. D'Cruz, and L. E. De Bault, "Distribution of human leukocyte antigen-ABC and-D/DR antigens in the unfixed human testis", American Journal of Reproductive Immunology and Microbiology, vol. 18, no. 2, pp. 47-51, 1988.
67. R. A. Morgan, N. Chinnasamy, D. Abate-Daga et al., "Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy", Journal of Immunotherapy, vol. 36, no. 2, pp. 133-151, 2013.
68. Y. Guilloux, S. Lucas, V. G. Brichard et al., "A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyl transferase V gene", The Journal of Experimental Medicine, vol. 183, no. 3, pp. 1173-1183, 1996.
69. B. J. Van Den Eynde, B. Gaugler, M. Probst-Kepper et al., "A new antigen recognized by cytolytic T lymphocytes on a human kidney tumor results from reverse strand transcription", Journal of Experimental Medicine, vol. 190, no. 12, pp. 1793-1799, 1999.
70. A. Moreau-Aubry, S. Le Guiner, N. Labarrière, M.-C. Gesnel, F. Jotereau, and R. Breathnach, "Aprocessed pseudogene codes for a new antigen recognized by a CD8+ T cell clone on melanoma", The Journal of Experimental Medicine, vol. 191, no. 9, pp. 1617-1624, 2000.
71. S. Ochsenreither, R. Majeti, T. Schmitt et al., "Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancertestis antigen", Blood, vol. 119, no. 23, pp. 5492-5501, 2012.
72. K. S. Hoek, N. C. Schlegel, O. M. Eichhoff et al., "Novel MITF targets identified using a two-step DNA microarray strategy", Pigment Cell and Melanoma Research, vol. 21, no. 6, pp. 665-676, 2008.
73. T. Wölfel, A. Van Pel, V. Brichard et al., "Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes", European Journal of Immunology, vol. 24, no. 3, pp. 759-764, 1994.
74. Y. Kawakami, S. Eliyahu, C. Jennings et al., "Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression", Journal of Immunology, vol. 154, no. 8, pp. 3961-3968, 1995.
75. H. Zarour, C. De Smet, F. Lehmann et al., "The majority of autologous cytolytic T-Lymphocyte clones derived from peripheral blood lymphocytes of a melanoma patient recognize an antigenic peptide derived from gene pme117/gp100", Journal of Investigative Dermatology, vol. 107, no. 1, pp. 63-67, 1996.
76. P. G. Coulie, V. Brichard, A. Van Pel et al., "A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas", The Journal of Experimental Medicine, vol. 180, no. 1, pp. 35-42, 1994.
77. Y. Kawakami, S. Eliyahu, K. Sakaguchi et al., "Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by themajority of HLA-A2-restricted tumor infiltrating lymphocytes", Journal of Experimental Medicine, vol. 180, no. 1, pp. 347-352, 1994.
78. R.-F. Wang, M. R. Parkhurst, Y. Kawakami, P. F. Robbins, and S. A. Rosenberg, "Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen", Journal of Experimental Medicine, vol. 183, no. 3, pp. 1137-1140, 1996.
79. R.-F. Wang, E. Appella, Y. Kawakami, X. Kang, and S. A. Rosenberg, "Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes", The Journal of Experimental Medicine, vol. 184, no. 6, pp. 2207-2216, 1996.
80. M. J. W. Visseren, A. Van Elsas, E. I. H. Van Der Voort et al., "CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells", Journal of Immunology, vol. 154, no. 8, pp. 3991-3998, 1995.
81. M. J. Pittet, D. Valmori, P. R. Dunbar et al., "High frequencies of naive Melan-A/MART-1-specific CD8+ T cells in a large proportion of human his to compatibility leukocyte antigen (HLA)-A2 individuals", Journal of Experimental Medicine, vol. 190, no. 5, pp. 705-715, 1999.
82. J. J. Nordlund, J. M. Kirkwood, B. M. Forget, G. Milton, D. M. Albert, and A. B. Lerner, "Vitiligo in patients with metastatic melanoma: a good prognostic sign", Journal of the American Academy of Dermatology, vol. 9, no. 5, pp. 689-696, 1983.
83. S. A. Rosenberg and D. E. White, "Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy", Journal of Immunotherapy, vol. 19, no. 1, pp. 81-84, 1996.
84. C. Yee, J. A. Thompson, P. Roche et al., "Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo", Journal of Experimental Medicine, vol. 192, no. 11, pp. 1637-1643, 2000.
85. B. M. Olson, T. P. Frye, L. E. Johnson et al., "HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase", Cancer Immunology, Immunotherapy, vol. 59, no. 6, pp. 943-953, 2010.
86. P. Correale, K. Walmsley, C. Nieroda et al., "In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen", Journal of the National Cancer Institute, vol. 89, no. 4, pp. 293-300, 1997.
87. S. Hammarström, "The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues", Seminars in Cancer Biology, vol. 9, no. 2, pp. 67-81, 1999.
88. B. Gaugler, N. Brouwenstijn, V. Vantomme et al., "A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma", Immunogenetics, vol. 44, no. 5, pp. 323-330, 1996.
89. C. F. Barker and R. E. Billingham, "Immunologically privileged sites", Advances in Immunology, vol. 25, pp. 1-54, 1978.
90. T. S. Griffith, T. Brunner, S. M. Fletcher, D. R. Green, and T. A. Ferguson, "Fas ligand-induced apoptosis as a mechanism of immune privilege", Science, vol. 270, no. 5239, pp. 1189-1192, 1995.
91. D. Abi-Hanna, D. Wakefield, and S. Watkins, "HLA antigens in ocular tissues. I. In vivo expression in human eyes", Transplantation, vol. 45, no. 3, pp. 610-613, 1988.
92. H. Ikeda, B. Lethé, F. Lehmann et al., "Characterization of an antigen that is recognized on amelanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor", Immunity, vol. 6, no. 2, pp. 199-208, 1997.
93. ∗0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis", The Journal of Experimental Medicine, vol. 193, no. 1, pp. 73-88, 2001.
94. M. Schmitz, P. Diestelkoetter, B. Weigle et al., "Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides", Cancer Research, vol. 60, no. 17, pp. 4845-4849, 2000.
95. S. M. Schmidt, K. Schag, M. R. Müller et al., "Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells", Blood, vol. 102, no. 2, pp. 571-576, 2003.
96. M. Röpke, J. Hald, P. Guldberg et al., "Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide", Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 25, pp. 14704-14707, 1996.
97. A. M. Barfoed, T. R. Petersen, A. F. Kirkin, P. Thor Straten, M. H. Claesson, and J. Zeuthen, "Cytotoxic T-lymphocyte clones, established by stimulation with the HLA-A2 binding p5365-73 wild type peptide loaded on dendritic cells in vitro, specifically recognize and lyse HLA-A2 tumour cells overexpressing the p53 protein", Scandinavian Journal of Immunology, vol. 51, no. 2, pp. 128-133, 2000.
98. M. H. Kraus, N. C. Popescu, S. C. Amsbaugh, and C. R. King, "Overexpression of the EGF receptor-related proto-oncogene erb B-2 in human mammary tumor cell lines by different molecular mechanisms", The EMBO Journal, vol. 6, no. 3, pp. 605-610, 1987.
99. D. J. Slamon, G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, and W. L. McGuire, "Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene", Science, vol. 235, no. 4785, pp. 177-182, 1987.
100. B. Fisk, T. L. Blevins, J. T. Wharton, and C. G. Ioannides, "Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines", The Journal of Experimental Medicine, vol. 181, no. 6, pp. 2109-2117, 1995.
101. K. Inoue, H. Ogawa, Y. Sonoda et al., "Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia", Blood, vol. 89, no. 4, pp. 1405-1412, 1997.
102. H. Ohminami, M. Yasukawa, and S. Fujita, "HLA class Irestricted lysis of leukemia cells by a CD8+ cytotoxic Tlymphocyte clone specific for WT1 peptide", Blood, vol. 95, no. 1, pp. 286-293, 2000.
103. A. M. Asemissen, U. Keilholz, S. Tenzer et al., "Identification of a highly immunogenic HLA-A01-binding T cell epitope of WT1", Clinical Cancer Research, vol. 12, no. 24, pp. 7476-7482, 2006.
104. A. G. Chapuis, G. B. Ragnarsson, H. N. Nguyen et al., "Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients", Science Translational Medicine, vol. 5, no. 174, Article ID 174ra27, 2013.
105. P. F. Robbins, Y.-C. Lu, M. El-Gamil et al., "Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells", Nature Medicine, vol. 19, no. 6, pp. 747-752, 2013.
106. Y.-C. Lu, X. Yao, Y. F. Li et al., "Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression", Journal of Immunology, vol. 190, no. 12, pp. 6034-6042, 2013.
107. N. Van Baren, J. F. Baurain, F. Brasseur, and P. G. Coulie, "Melanoma antigens recognized by T lymphocytes", in Targeted Therapeutics in Melanoma, T. F. Gajewski and F. S. Hodi, Eds., Current Clinical Oncology, pp. 187-205, Springer Science+ Business Media, LLC, 2012.
108. L. A. Johnson, R. A. Morgan, M. E. Dudley et al., "Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen", Blood, vol. 114, no. 3, pp. 535-546, 2009.
109. C. H. J. Lamers, S. Sleijfer, A. G. Vulto et al., "Treatment of metastatic renal cell carcinomawith autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience", Journal of Clinical Oncology, vol. 24, no. 13, pp. e20-e22, 2006.
110. M. R. Parkhurst, J. C. Yang, R. C. Langan et al., "T cells targeting carcinoembryonic antigen can mediate regression ofmetastatic colorectal cancer but induce severe transient colitis", Molecular Therapy, vol. 19, no. 3, pp. 620-626, 2011.
111. R. A. Morgan, J. C. Yang, M. Kitano, M. E. Dudley, C. M. Laurencot, and S. A. Rosenberg, "Case report of a serious adverse event following the administration of t cells transduced with a chimeric antigen receptor recognizing ERBB2", Molecular Therapy, vol. 18, no. 4, pp. 843-851, 2010.
112. B. J. Cameron, A. B. Gerry, J. Dukes et al., "Identification of a titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells", Science Translational Medicine, vol. 5, no. 197, Article ID 197ra103, 2013.
113. G. P. Linette, E. A. Stadtmauer, M. V. Maus et al., "Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma", Blood, vol. 122, no. 6, pp. 863-871, 2013.
114. S. Kageyama, T. J. Tsomides, Y. Sykulev, and H. N. Eisen, "Variations in the number of peptide-MHC class I complexes required to activate cytotoxic T cell responses", Journal of Immunology, vol. 154, no. 2, pp. 567-576, 1995.
115. N. Vigneron and B. Van Den Eynde, "Proteasome subtypes and regulators in the processing of antigenic peptides presented by class I molecules of the major his to compatibility complex", Biomolecules, vol. 4, no. 4, pp. 994-1025, 2014.
116. M. T. Michalek, E. P. Grant, C. Gramm, A. L. Goldberg, and K. L. Rock, "A role for the ubiquitin-dependent proteolytic pathway in MHC class I-restricted antigen presentation", Nature, vol. 363, no. 6429, pp. 552-554, 1993.
117. K. L. Rock, C. Gramm, L. Rothstein et al., "Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules", Cell, vol. 78, no. 5, pp. 761-771, 1994.
118. S. Morel, F. Lévy, O. Burlet-Schiltz et al., "Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells", Immunity, vol. 12, no. 1, pp. 107-117, 2000.
119. S. Ottaviani, Y. Zhang, T. Boon, and P. Van Der Bruggen, "A MAGE-1 antigenic peptide recognized by human cytolytic T lymphocytes on HLA-A2 tumor cells", Cancer Immunology, Immunotherapy, vol. 54, no. 12, pp. 1214-1220, 2005.
120. N. Parmentier, V. Stroobant, D. Colau et al., "Production of an antigenic peptide by insulin-degrading enzyme", Nature Immunology, vol. 11, no. 5, pp. 449-454, 2010.
121. J. Löwe, D. Stock, B. Jap, P. Zwickl, W. Baumeister, and R. Huber, "Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 Å resolution", Science, vol. 268, no. 5210, pp. 533-539, 1995.
122. M. Groll, L. Ditzel, J. Löwe et al., "Structure of 20S proteasome from yeast at 2.4 Å resolution", Nature, vol. 386, no. 6624, pp. 463-471, 1997.
123. E. Seemuller, A. Lupas, D. Stock, J. Lowe, R. Huber, and W. Baumeister, "Proteasome from Thermoplasma acidophilum: a threonine protease", Science, vol. 268, no. 5210, pp. 579-582, 1995.
124. M. Groll and R. Huber, "Substrate access and processing by the 20S proteasome core particle", The International Journal of Biochemistry & Cell Biology, vol. 35, no. 5, pp. 606-616, 2003.
125. W. Heinemeyer, A. Cruhler, V. Mohrle, Y. Mahe, and D. H. Wolf, "PRE2, highly homologous to the human major histocompatibility complex-linked Ring10 gene, codes for a yeast proteasome subunit necessary for chymotryptic activity and degradation of ubiquitinated proteins", The Journal of Biological Chemistry, vol. 268, no. 7, pp. 5115-5120, 1993.
126. C. Enenkel, "PRE3, highly homologous to the human major histocompatibility complex-linked LMP2 (RING12) gene, codes for a yeast proteasome subunit necessary for the peptidylglutamylpeptide hydrolyzing activity", FEBS Letters, vol. 341, no. 2-3, pp. 193-196, 1994.
127. W. Heinemeyer, M. Fischer, T. Krimmer, U. Stachon, and D. H. Wolf, "The active sites of the eukaryotic 20 S proteasome and their involvement in subunit precursor processing", Journal of Biological Chemistry, vol. 272, no. 40, pp. 25200-25209, 1997.
128. T. P. Dick, A. K. Nussbaum, M. Deeg et al., "Contribution of proteasomal β-subunits to the cleavage of peptide substrates analyzed with yeast mutants", The Journal of Biological Chemistry, vol. 273, no. 40, pp. 25637-25646, 1998.
129. R. Gueckel, C. Enenkel, D. H. Wolf, and W. Hilt, "Mutations in the yeast proteasome β-type subunit Pre3 uncover positiondependent effects on proteasomal peptidase activity and in vivo function", Journal of Biological Chemistry, vol. 273, no. 31, pp. 19443-19452, 1998.
130. U. Salzmann, S. Kral, B. Braun et al., "Mutational analysis of subunit iβ2 (MECL-1) demonstrates conservation of cleavage specificity between yeast and mammalian proteasomes", FEBS Letters, vol. 454, no. 1-2, pp. 11-15, 1999.
131. A. K. Nussbaum, T. P. Dick, W. Keilholz et al., "Cleavage motifs of the yeast 20S proteasome β subunits deduced fromdigests of enolase 1", Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 21, pp. 12504-12509, 1998.
132. R. E. M. Toes, A. K. Nussbaum, S. Degermann et al., "Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products", The Journal of Experimental Medicine, vol. 194, no. 1, pp. 1-12, 2001.
133. N. Vigneron, V. Stroobant, J. Chapiro et al., "An antigenic peptide produced by peptide splicing in the proteasome", Science, vol. 304, no. 5670, pp. 587-590, 2004.
134. K.-I. Hanada, J. W. Yewdell, and J. C. Yang, "Immune recognition of a human renal cancer antigen through post-translational protein splicing", Nature, vol. 427, no. 6971, pp. 252-256, 2004.
135. E. H. Warren, N. J. Vigneron, M. A. Gavin et al., "An antigen produced by splicing of noncontiguous peptides in the reverse order", Science, vol. 313, no. 5792, pp. 1444-1447, 2006.
136. A. Dalet, N. Vigneron, V. Stroobant, K.-I. Hanada, and B. J. Van Den Eynde, "Splicing of distant peptide fragments occurs in the proteasome by transpeptidation and produces the spliced antigenic peptide derived from fibroblast growth factor-5", Journal of Immunology, vol. 184, no. 6, pp. 3016-3024, 2010.
137. A. Michaux, P. Larrieu, V. Stroobant et al., "A spliced antigenic peptide comprising a single spliced amino acid is produced in the proteasome by reverse splicing of a longer peptide fragment followed by trimming", The Journal of Immunology, vol. 192, no. 4, pp. 1962-1971, 2014.
138. M. Mishto, A. Goede, K. T. Taube et al., "Driving forces of proteasome-catalyzed peptide splicing in yeast and humans", Molecular and Cellular Proteomics, vol. 11, no. 10, pp. 1008-1023, 2012.
139. T. A. Griffin, D. Nandi, M. Cruz et al., "Immunoproteasome assembly: cooperative incorporation of interferon γ (IFN-γ) - inducible subunits", Journal of Experimental Medicine, vol. 187, no. 1, pp. 97-104, 1998.
140. J. Driscoll, M. G. Brown, D. Finley, and J. J. Monaco, "MHClinked LMP gene products specifically alter peptidase activities of the proteasome", Nature, vol. 365, no. 6443, pp. 262-264, 1993.
141. M. Gaczynska, K. L. Rock, and A. L. Goldberg, "γ-Interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes", Nature, vol. 365, no. 6443, pp. 264-267, 1993.
142. B. Guillaume, J. Chapiro, V. Stroobant et al., "Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules", Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 43, pp. 18599-18604, 2010.
143. H. J. Fehling, W. Swat, C. Laplace et al., "MHC class I expression in mice lacking the proteasome subunit LMP-7", Science, vol. 265, no. 5176, pp. 1234-1237, 1994.
144. L. Van Kaer, P. G. Ashton-Rickardt, M. Eichelberger et al., "Altered peptidase and viral-specific T cell response in LMP2 mutant mice", Immunity, vol. 1, no. 7, pp. 533-541, 1994.
145. E. Z. Kincaid, J. W. Che, I. York et al., "Mice completely lacking immunoproteasomes show major changes in antigen presentation", Nature Immunology, vol. 13, no. 2, pp. 129-135, 2012.
146. B. Boes, H. Hengel, T. Ruppert, G. Multhaup, U. H. Koszinowski, and P.-M. Kloetzel, "Interferon γ stimulationmodulates the proteolytic activity and cleavage site preference of 20S mouse proteasomes", The Journal of Experimental Medicine, vol. 179, no. 3, pp. 901-909, 1994.
147. D. De Verteuil, T. L. Muratore-Schroeder, D. P. Granados et al., "Deletion of immunoproteasome subunits imprints on the transcriptome and has a broad impact on peptides presented by major histocompatibility complex I molecules", Molecular and Cellular Proteomics, vol. 9, no. 9, pp. 2034-2047, 2010.
148. E. S. Schultz, J. Chapiro, C. Lurquin et al., "The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome", The Journal of Experimental Medicine, vol. 195, no. 4, pp. 391-399, 2002.
149. J. Chapiro, S. Claverol, F. Piette et al., "Destructive cleavage of antigenic peptides either by the immunoproteasome or by the standard proteasome results in differential antigen presentation", The Journal of Immunology, vol. 176, no. 2, pp. 1053-1061, 2006.
150. B. Guillaume, V. Stroobant, M.-P. Bousquet-Dubouch et al., "Analysis of the processing of seven human tumor antigens by intermediate proteasomes", The Journal of Immunology, vol. 189, no. 7, pp. 3538-3547, 2012.
151. A. Dalet, V. Stroobant, N. Vigneron, and B. J. Van Den Eynde, "Differences in the production of spliced antigenic peptides by the standard proteasome and the immunoproteasome", European Journal of Immunology, vol. 41, no. 1, pp. 39-46, 2011.
152. B. Dahlmann, T. Ruppert, L. Kuehn, S. Merforth, and P.-M. Kloetzel, "Different proteasome subtypes in a single tissue exhibit different enzymatic properties", Journal of Molecular Biology, vol. 303, no. 5, pp. 643-653, 2000.
153. D. J. Kingsbury, T. A. Griffin, and R. A. Colbert, "Novel propeptide function in 20 S proteasome assembly influences β subunit composition", Journal of Biological Chemistry, vol. 275, no. 31, pp. 24156-24162, 2000.
154. M. De, K. Jayarapu, L. Elenich, J. J. Monaco, R. A. Colbert, and T. A. Griffin, "β2 subunit propeptides influence cooperative proteasome assembly", The Journal of Biological Chemistry, vol. 278, no. 8, pp. 6153-6159, 2003.
155. U. Seifert, C. Maranón, A. Shmueli et al., "An essential role for tripeptidyl peptidase in the generation of an MHC class I epitope", Nature Immunology, vol. 4, no. 4, pp. 375-379, 2003.
156. S. Guil, M. Rodríguez-Castro, F. Aguilar, E. M. Villasevil, L. C. Antón, and M. Del Val, "Need for tripeptidyl-peptidase II in major histocompatibility complex class I viral antigen processing when proteasomes are detrimental", Journal of Biological Chemistry, vol. 281, no. 52, pp. 39925-39934, 2006.
157. J. H. Kessler, S. Khan, U. Seifert et al., "Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes", Nature Immunology, vol. 12, no. 1, pp. 45-53, 2011.
158. X. Z. Shen, S. Billet, C. Lin et al., "The carboxypeptidase ACE shapes the MHCclass I peptide repertoire", Nature Immunology, vol. 12, no. 11, pp. 1078-1085, 2011.
159. N. Vigneron and B. J. Van Den Eynde, "Proteasome subtypes and the processing of tumor antigens: increasing antigenic diversity", Current Opinion in Immunology, vol. 24, no. 1, pp. 84-91, 2012.
160. A. Nil, E. Firat, V. Sobek, K. Eichmann, and G. Niedermann, "Expression of housekeeping and immunoproteasome subunit genes is differentially regulated in positively and negatively selecting thymic stroma subsets", European Journal of Immunology, vol. 34, no. 10, pp. 2681-2689, 2004.
161. J. Gotter, B. Brors, M. Hergenhahn, and B. Kyewski, "Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters", The Journal of Experimental Medicine, vol. 199, no. 2, pp. 155-166, 2004.
162. I. J. Huijbers, S. M. Soudja, C. Uyttenhove et al., "Minimal tolerance to a tumor antigen encoded by a cancer-germline gene", Journal of Immunology, vol. 188, no. 1, pp. 111-121, 2012.
163. J. D. Wolchok, B. Neyns, G. Linette et al., "Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study", The Lancet Oncology, vol. 11, no. 2, pp. 155-164, 2010.
164. W. H. Kruit, N. Van Baren, Y. Humblet et al., "Phase I/II study of vaccination with MAGE-3 protein plus immunological adjuvant SB AS-2 in HLAClass I selected patientswith MAGE-3 positive tumors", Proceedings of the American Society of Clinical Oncology, vol. 19, abstract 1882, p. 479a, 2000.
165. W. H. J. Kruit, H. H. Van Ojik, V. G. Brichard et al., "Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma", International Journal of Cancer, vol. 117, no. 4, pp. 596-604, 2005.
166. N. Van Baren, M.-C. Bonnet, B. Dréno et al., "Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells", Journal of Clinical Oncology, vol. 23, no. 35, pp. 9008-9021, 2005.
167. J. Carrasco, A. Van Pel, B. Neyns et al., "Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells", Journal of Immunology, vol. 180, no. 5, pp. 3585-3593, 2008.
168. C. Lurquin, B. Lethé, E. De Plaen et al., "Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinatedwith a MAGE tumor antigen", The Journal of Experimental Medicine, vol. 201, no. 2, pp. 249-257, 2005.
169. I. S. Van Houdt, B. J. R. Sluijter, L. M. Moesbergen et al., "Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression", International Journal of Cancer, vol. 123, no. 3, pp. 609-615, 2008.
170. M. J. Maeurer, S. M. Gollin, D. Martin et al., "Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-Aantigen", The Journal of Clinical Investigation, vol. 98, no. 7, pp. 1633-1641, 1996.
171. J. Kamarashev, S. Ferrone, B. Seifert et al., "TAP1 down-regulation in primary melanoma lesions: an independent marker of poor prognosis", International Journal of Cancer, vol. 95, no. 1, pp. 23-28, 2001.
172. M. Vitale, R. Rezzani, L. Rodella et al., "HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions", Cancer Research, vol. 58, no. 4, pp. 737-742, 1998.
173. T. Ogino, H. Shigyo, H. Ishii et al., "HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker", Cancer Research, vol. 66, no. 18, pp. 9281-9289, 2006.
174. N. Vigneron, D. R. Peaper, R. M. Leonhardt, and P. Cresswell, "Functional significance of tapasin membrane association and disulfide linkage to ERp57 in MHC class I presentation", European Journal of Immunology, vol. 39, no. 9, pp. 2371-2376, 2009.
175. M. Platten, W. Wick, and B. J. Van Den Eynde, "Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion", Cancer Research, vol. 72, no. 21, pp. 5435-5440, 2012.
176. A. Pedoeem, I. Azoulay-Alfaguter, M. Strazza, G. J. Silverman, and A. Mor, "Programmed death-1 pathway in cancer and autoimmunity", Clinical Immunology, vol. 153, no. 1, pp. 145-152, 2014.
177. B. Li, M. Vanroey, C. Wang, T.-H. T. Chen, A. Korman, and K. Jooss, "Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor-secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors", Clinical Cancer Research, vol. 15, no. 5, pp. 1623-1634, 2009.
178. A. J. R. McGray, D. Bernard, R. Hallett et al., "Combined vaccination and immunostimulatory antibodies provides durable cure of murine melanoma and induces transcriptional changes associated with positive outcome in human melanoma patients", Onco Immunology, vol. 1, no. 4, pp. 419-431, 2012.
179. J. Duraiswamy, G. J. Freeman, and G. Coukos, "Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer", Cancer Research, vol. 73, no. 23, pp. 6900-6912, 2013.
180. J. Duraiswamy, K. M. Kaluza, G. J. Freeman, and G. Coukos, "Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors", Cancer Research, vol. 73, no. 12, pp. 3591-3603, 2013.
181. C. Wölfel, I. Drexler, A. Van Pel et al., "Transporter (TAP)- and proteasome-independent presentation of a melanoma-associated tyrosinase epitope", International Journal of Cancer, vol. 88, no. 3, pp. 432-438, 2000.
182. F. El Hage, V. Stroobant, I. Vergnon et al., "Preprocalcitonin signal peptide generates a cytotoxic T lymphocyte-defined tumor epitope processed by a proteasome-independent pathway", Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 29, pp. 10119-10124, 2008.
183. C. C. Oliveira and T. Van Hall, "Importance of TAP-independent processing pathways", Molecular Immunology, vol. 55, no. 2, pp. 113-116, 2013.
184. C. C. Oliveira, B. Querido, M. Sluijter, J. Derbinski, S. H. Van Der Burg, and T. Van Hall, "Peptide transporter TAP mediates between competing antigen sources generating distinct surface MHC class I peptide repertoires", European Journal of Immunology, vol. 41, no. 11, pp. 3114-3124, 2011.
185. U. J. E. Seidel, C. C. Oliveira, M. H. Lampen, and T. Van Hall, "A novel category of antigens enabling CTL immunity to tumor escape variants: Cinderella antigens", Cancer Immunology, Immunotherapy, vol. 61, no. 1, pp. 119-125, 2012.
186. T. I. Näslund, C. Uyttenhove, E. K. L. Nordström et al., "Comparative prime-boost vaccinations using semliki forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective centralmemory CTL response against the P815 tumor", Journal of Immunology, vol. 178, no. 11, pp. 6761-6769, 2007.
187. S. J. Dunachie and A. V. S. Hill, "Prime-boost strategies for malaria vaccine development", The Journal of Experimental Biology, vol. 206, part 21, pp. 3771-3779, 2003.
188. A. C. Moore and A. V. S. Hill, "Progress in DNA-based heterologous prime-boost immunization strategies for malaria", Immunological Reviews, vol. 199, pp. 126-143, 2004.
189. A. J. McMichael, "HIV vaccines", Annual Review of Immunology, vol. 24, no. 1, pp. 227-255, 2006.
190. C. Larocca and J. Schlom, "Viral vector-based therapeutic cancer vaccines", Cancer Journal, vol. 17, no. 5, pp. 359-371, 2011.